An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
about
Structure and function of Gab2 and its role in cancer (Review)Targeting of erbB3 receptor to overcome resistance in cancer treatmentRegulation of ERBB3/HER3 signaling in cancerCIViC databaseAn Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinBlocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.New perspectives on targeted therapy in ovarian cancerCellular effects of HER3-specific affibody moleculesDpp-induced Egfr signaling triggers postembryonic wing development in Drosophila.Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse.Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsPicking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian CancerCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaRandomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Pharmacological targeting of the pseudokinase Her3Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversificationExpression of NRG1 and its receptors in human bladder cancer.The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.MiR-125a-3p regulates glioma apoptosis and invasion by regulating Nrg1An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaExamination of HER3 targeting in cancer using monoclonal antibodiesEngineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs.Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities.Development of small molecules targeting the pseudokinase Her3.Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cellsA recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
P2860
Q26825507-52FED0E1-01E2-4D75-A0B2-7835E28C8E53Q26864668-7FC7CC62-56DF-4254-8618-0025E6FBEABCQ27024334-839702EE-8A4B-4C23-8E5F-DDF23E3A158BQ27612411-4DB598B5-A29F-4835-A90F-0A47B03D536DQ27679463-839AFE2F-2863-4D12-A92D-DA05D4FD027AQ27852078-726E66D8-68D7-45D9-9C2E-3E2E9824A978Q28082524-FB48E405-5B7D-44E0-9BDD-1ADFBA868A29Q28727774-1B0B9516-BB97-48DD-B34A-4BC390793B64Q30538195-70DF15B7-D246-4004-840E-F7D363B8A644Q31134061-1FD4E66A-A77F-4081-B349-647FCF1AC1ACQ33597555-747D33F5-240E-4F29-8855-8257A706E2FDQ33601653-0DCE8CDD-6B1D-4B28-AE8F-A8659F0A7CD4Q33669407-56FFECBA-9BE6-4840-906A-258CB5F3AA3FQ33691823-F2E1D454-9FEC-4A3F-8020-1C357FF84457Q33756409-204725AD-669D-4D7A-8C25-60DE444CB075Q33875560-02EEB0E3-2675-4781-84FC-8A1E5D59E885Q33903078-1CD34A1B-53B3-4A3B-BCCB-0CD856935120Q33916606-890B7984-D39B-40B8-8770-369153E0B52EQ33917876-47C9F17F-D3CA-40DA-A070-8C4C959EEE04Q34349389-E037AAEF-78AA-4D89-8165-45E30B18511FQ34490603-AA0A418E-998A-4E89-B357-E9ABA6166049Q34514043-FAF16EF6-6FB0-44BF-90B0-6BAD3AE82EBAQ34619329-DBC57AE3-CB8C-4781-B370-D9EDD709CAD4Q34722687-DC606CFA-7C65-4174-9A74-7989B1DC2A4FQ34745805-7BFC7749-00D8-4D16-BBB5-AE69B39F5BE5Q34806737-472ECF28-19ED-4F1D-A11F-4FB37E61EA5DQ34822660-D64DBE5D-8C1A-416A-919A-CA1F000B33E0Q34926232-6FBB9A17-A609-4D1A-9C9F-9D7E4C912325Q35031462-782082E0-FF73-4D3E-BFBB-C095FD349BF9Q35145024-4DAA79F6-8885-4B8E-8534-3E99882BBC5FQ35153559-73FB195F-5DF4-4D7F-942A-8331C4BDD4A1Q35390011-F3648FF0-FB1E-45C4-86C4-760436928790Q35479646-B39F2D4C-9ED1-4493-87BC-6C71C12ADBCEQ35621829-54A8E066-8628-4493-A36B-FE80E6A3158BQ35638363-541996E5-9134-4850-9E1D-6C20CA10599AQ35669652-B13FCD1C-EAC6-4274-BF28-D3ADFB2930BCQ35683214-127F97C0-D5AA-40EB-9F56-F02DBE931CAAQ35791377-B8B4FF37-3D06-4963-A90B-0C9E7C4DAE94Q35888647-23F2CC7A-D6C1-4DC1-95A5-5E078858CF04Q35890128-FDF87D3C-B069-4BF3-9F4C-D108895AC39C
P2860
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@ast
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en-gb
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@nl
type
label
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@ast
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en-gb
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@nl
altLabel
An Activated ErbB3/NRG1 Autocr ...... ration in Ovarian Cancer Cells
@en
prefLabel
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@ast
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@en-gb
An activated ErbB3/NRG1 autocr ...... ration in ovarian cancer cells
@nl
P2093
P2860
P50
P3181
P1433
P1476
An activated ErbB3/NRG1 autocr ...... ation in ovarian cancer cells.
@en
P2093
Anna Schinzel
Birgit Schoeberl
David Batt
David M Livingston
Eleanor Fleming
Huiying Piao
Jinyun Chen
Joyce F Liu
Karen Yuan
Qing Sheng
P2860
P304
P3181
P356
10.1016/J.CCR.2009.12.047
P407
P577
2010-03-16T00:00:00Z